Skip to main content
Erschienen in: Clinical and Translational Oncology 9/2020

02.03.2020 | Research Article

DNA damage response proteins and its role in tumor progression of uveal melanoma with patient outcome

verfasst von: S. Kashyap, J. Jha, M. K. Singh, L. Singh, S. Sen, J. Kaur, M. S. Bajaj, N. Pushker

Erschienen in: Clinical and Translational Oncology | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The role of DNA damage response (DDR) proteins is poorly understood in uveal melanoma. ATR belongs to one of those proteins that induce DDR by arresting the cell cycle which leads to DNA repair. ATR is localized at position 23 on the same chromosome 3 where BAP1 is located at position 21.1 which is a known poor prognostic marker of UM. The aim of our study is to detect the expression of ATR at the protein and RNA levels and determine its prognostic significance.

Methods

Expression of nuclear ATR was investigated on sixty-nine UM patients. Formalin-fixed paraffin-embedded choroidal melanoma samples were taken to evaluate the expression of ATR. Fifty samples were also validated by real-time PCR. Results of both protein and mRNA were then correlated with clinicopathological parameters. To determine the prognostic significance, Kaplan–Meier and multivariate analyses were performed.

Results

Loss of ATR protein was seen in 72% cases which was statistically significant with epithelioid cell type (p = 0.005), tumor thickness (p = 0.016), mitotic figures (p = 0.001) and BAP1 loss (p < 0.001). At the transcriptional level loss of ATR was seen in 76% cases which were statistically significant with metastasis (p = 0.046), staging (0.044) and loss of BAP1 (p = 0.022). On multivariate analysis loss of ATR and tumor staging came out to be independent prognostic parameters.

Conclusion

Our data suggest that ATR might serve as a potential prognostic marker in UM patients and could serve as a potential therapeutic target.
Literatur
1.
Zurück zum Zitat Singh M, Durairaj P, Yeung J. Uveal melanoma: a review of the literature. Oncol Ther. 2018;6:87–104.CrossRef Singh M, Durairaj P, Yeung J. Uveal melanoma: a review of the literature. Oncol Ther. 2018;6:87–104.CrossRef
2.
Zurück zum Zitat O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60:547–60.CrossRef O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60:547–60.CrossRef
3.
Zurück zum Zitat Harbour JW, Onken MD, Roberson EDO, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410–3.CrossRef Harbour JW, Onken MD, Roberson EDO, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410–3.CrossRef
5.
Zurück zum Zitat Eletr ZM, Yin L, Wilkinson KD. BAP1 is phosphorylated at serine 592 in S-phase following DNA damage. FEBS Lett. 2013;587:3906–11.CrossRef Eletr ZM, Yin L, Wilkinson KD. BAP1 is phosphorylated at serine 592 in S-phase following DNA damage. FEBS Lett. 2013;587:3906–11.CrossRef
6.
Zurück zum Zitat Fokas E, Prevo R, Hammond EM, et al. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev. 2013;40:109–17.CrossRef Fokas E, Prevo R, Hammond EM, et al. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev. 2013;40:109–17.CrossRef
7.
Zurück zum Zitat Menezes DL, Holt J, Tang Y, et al. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function. Mol Cancer Res. 2015;13:120–9.CrossRef Menezes DL, Holt J, Tang Y, et al. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function. Mol Cancer Res. 2015;13:120–9.CrossRef
8.
Zurück zum Zitat Tanaka A, Weine S, Nagy N, et al. Germline mutation in ATR in autosomal-dominant oropharyngeal cancer syndrome. AJHG. 2012;90:511–7.CrossRef Tanaka A, Weine S, Nagy N, et al. Germline mutation in ATR in autosomal-dominant oropharyngeal cancer syndrome. AJHG. 2012;90:511–7.CrossRef
9.
Zurück zum Zitat Bertoni F, Codegoni AM, Furlan D, et al. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer. 1999;26:176–80.CrossRef Bertoni F, Codegoni AM, Furlan D, et al. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer. 1999;26:176–80.CrossRef
10.
Zurück zum Zitat Menoyo A, Alazzouzi H, Espín E, et al. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res. 2001;61:7727–30.PubMed Menoyo A, Alazzouzi H, Espín E, et al. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res. 2001;61:7727–30.PubMed
11.
Zurück zum Zitat Lewis KA, Mullany S, Thomas B, et al. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. Cancer Res. 2005;65:7091–5.CrossRef Lewis KA, Mullany S, Thomas B, et al. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. Cancer Res. 2005;65:7091–5.CrossRef
12.
Zurück zum Zitat van Essen TH, van Pelt SI, Versluis M, et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol. 2014;98:1738–43.CrossRef van Essen TH, van Pelt SI, Versluis M, et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol. 2014;98:1738–43.CrossRef
13.
Zurück zum Zitat Chen CF, Ruiz-Vega R, Vasudeva P, et al. ATR mutations promote the growth of melanoma tumors by modulating the immune microenvironment. Cell Rep. 2017;18:2331–42.CrossRef Chen CF, Ruiz-Vega R, Vasudeva P, et al. ATR mutations promote the growth of melanoma tumors by modulating the immune microenvironment. Cell Rep. 2017;18:2331–42.CrossRef
14.
Zurück zum Zitat Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989–98.CrossRef Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989–98.CrossRef
15.
Zurück zum Zitat Diniz MG, Silva Jde F, de Souza FT, et al. Association between cell cycle gene transcription and tumor size in oral squamous cell carcinoma. Tumour Biol. 2015;36:9717–22.CrossRef Diniz MG, Silva Jde F, de Souza FT, et al. Association between cell cycle gene transcription and tumor size in oral squamous cell carcinoma. Tumour Biol. 2015;36:9717–22.CrossRef
16.
Zurück zum Zitat Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11:255–63.CrossRef Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11:255–63.CrossRef
17.
Zurück zum Zitat McLean MJ, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 1977;95:48–58.CrossRef McLean MJ, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 1977;95:48–58.CrossRef
18.
Zurück zum Zitat de la Cruz PO, Jr Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65:112–5.CrossRef de la Cruz PO, Jr Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65:112–5.CrossRef
19.
Zurück zum Zitat Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389–98.CrossRef Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389–98.CrossRef
20.
Zurück zum Zitat Bujara K. Necrotic malignant melanomas of the choroid and ciliary body. A clinicopathological and statistical study. Graefes Arch Clin Exp Ophthalmol. 1982;219:40–3.CrossRef Bujara K. Necrotic malignant melanomas of the choroid and ciliary body. A clinicopathological and statistical study. Graefes Arch Clin Exp Ophthalmol. 1982;219:40–3.CrossRef
21.
Zurück zum Zitat Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 2008;130:1091–103.CrossRef Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 2008;130:1091–103.CrossRef
22.
Zurück zum Zitat Zighelboim I, Schmidt AP, Gao F, et al. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol. 2009;27:3091–6.CrossRef Zighelboim I, Schmidt AP, Gao F, et al. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol. 2009;27:3091–6.CrossRef
Metadaten
Titel
DNA damage response proteins and its role in tumor progression of uveal melanoma with patient outcome
verfasst von
S. Kashyap
J. Jha
M. K. Singh
L. Singh
S. Sen
J. Kaur
M. S. Bajaj
N. Pushker
Publikationsdatum
02.03.2020
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 9/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02281-x

Weitere Artikel der Ausgabe 9/2020

Clinical and Translational Oncology 9/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.